ArticleMedical journal of Zambia2025
Analysis of the loss of Epithelial Cadherin expression in gastric cancer in Zambia.
Article in Medical journal of Zambia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Background: Gastric cancer (GC) is the one of the most common cancers globally and can be classified as diffuse, intestinal or mixed. Epithelial-cadherin (E-cadherin) is a transmembrane glycoprotein which plays a role in maintaining cell shape and extracellular matrix and its loss or reduction has been observed in gastric carcinogenesis. The aim of the study was to determine the proportion of loss of E-cadherin expression in GC. Methods: Archival formalin fixed paraffin embedded GC tissues and their basic characteristics were retrieved from the histopathology laboratory at the University Teaching Hospital in Lusaka. Sections of the tissue were stained with haematoxylin and eosin to allow for typing of the GC and immunohistochemically stained with an antibody against E-cadherin. Data analysis was conducted using Stata version 15. Results: We successfully stained 31 archival GC tissues after excluding those not meeting quality checks. Among the samples included, 18 (58%) were from females. The median age was 51 years, IQR 40-68. Overall, 11 (36%) showed loss of E-cadherin expression. Young age was associated with E-cadherin loss (p=0.02). Histologically, 10 (32%) of the GC were of the diffuse type, 18 (58%) intestinal type and 3 (10%) mixed type. E-cadherin loss was significantly higher in diffuse type 7 (70%) than the Intestinal 2 (18%) or 2 (67%) the mixed types (p=0.003). In multivariable analysis, the difference remained significant (p=0.041). The proportion of E-cadherin loss was higher in tumours located in the cardia, 57%, when compared to those that were non-cardia in location, 29%, but the difference was not statistically significant [OR 3.2; 95% CI 0.4-27, p=0.21]. Conclusions: Loss of E-cadherin expression is associated with a younger age at diagnosis and with diffuse type gastric cancer. Results from this study could contribute toward patient prognostication and possibly influence therapeutic choices for GC patients in Zambia.
Indexed as
Identifiers
40520443PMC12165256What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.